T-CURX
Desconocido
T2EVOLVE: Accelerating Development and Improving Access to CAR and TCR engineered T cell therapy
TCURX GMBH
participó en un
H2020:
H2020-JTI-IMI2-2019-18-two-stage
Immune cells that are empowered by gene-engineering to seek and destroy cancer cells (engineered T cell therapy) constitute a transformative...
2020-11-24 - 2025-12-31 | Financiado
2020-11-24 - 2025-12-31 | Financiado
imSAVAR: Immune Safety Avatar nonclinical mimicking of the immune system effects of immunomodulatory therapi...
TCURX GMBH
participó en un
H2020:
H2020-JTI-IMI2-2018-15-two-stage
The vision of Immune Safety Avatar (imSAVAR) is to develop a platform for integrated nonclinical assessments of immunomodulatory therapy saf...
2019-11-18 - 2025-11-30 | Financiado
2019-11-18 - 2025-11-30 | Financiado
CARAMBA: SLAMF7 CAR T cells prepared by Sleeping Beauty gene transfer for immunotherapy of multiple myeloma...
TCURX GMBH
participó en un
H2020:
H2020-SC1-2016-2017
CARAMBA is proposing to use the revolutionary CAR-T cell technology to tackle multiple myeloma, a rare and incurable hematologic malignancy....
2017-11-22 - 2023-06-30 | Financiado
2017-11-22 - 2023-06-30 | Financiado
* No se disponen de datos de la empresa actual.